Stem Cells Therapy for Diabetes Mellitus Type 1. An Update on Safety and Outcomes

Author(s): Iana Malasevskaia, Ahmed Ali Al-Awadhi

Type 1 diabetes mellitus (T1DM) is the most prevalent chronic autoimmune illness in children and young adults. It is defined by the loss of pancreatic cells, which causes the body to produce insufficient amounts of insulin and lead to hyperglycemia. Patients with T1DM have a great chance of recovery with stem cell therapy. There have been advancements in stem cell-based therapies for T1DM with the development of research on stem cell treatment for a variety of conditions. Before stem cell therapy for diabetic patients is clinically viable, there are still a lot of unresolved problems. In this review, we highlight recent developments in stem cell-based treatments for T1DM as well as methods for creating insulin-producing cells (IPCs) from various precursor cells. The aim of this study is to investigate the safety and outcomes of stem cells therapy for T1DM.